Salcaprozate sodium
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H20NNaO4 |
Molar mass | 301.318 g·mol−1 |
3D model (JSmol) | |
| |
|
Salcaprozate sodium (SNAC) is an intestinal permeation enhancer that is used in drug formulations particularly for macromolecules and poorly permeable compounds.[1][2] SNAC has been used in formulations of drugs that have undergone clinical trials and has achieved generally recognized as safe (GRAS) status, with U.S. Food and Drug Administration approval for use in a medical food products.[1][2]
An oral formulation of semaglutide that includes SNAC has been approved for use human use in the United States and Europe.[3]
References
[edit]- ^ a b Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ (February 2019). "Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)". Pharmaceutics. 11 (2): 78. doi:10.3390/pharmaceutics11020078. PMC 6410172. PMID 30781867.
- ^ a b Kommineni N, Sainaga Jyothi VG, Butreddy A, Raju S, Shapira T, Khan W, et al. (March 2023). "SNAC for Enhanced Oral Bioavailability: An Updated Review". Pharmaceutical Research. 40 (3): 633–650. doi:10.1007/s11095-022-03459-9. PMID 36539668.
- ^ Selvarajan R, Subramanian R (2023). "A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 16: 1709–1720. doi:10.2147/DMSO.S385196. PMC 10259523. PMID 37312901.